Structures by: Johnston A.
Total: 96
5H-dibenz(b,f)azepine-5-carboxamide 10,11-dihydro-5H- dibenz(b,f)azepine-5-carboxamide (1/1)
0.5(C15H12N2O1),0.5(C15H14N2O1)
CrystEngComm (2006) 8, 10 746
a=9.088(2)Å b=10.425(4)Å c=25.005(7)Å
α=90.00° β=90.00° γ=90.00°
10,11-Dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide
C16H15NO
CrystEngComm (2008) 10, 1 26
a=5.6491(1)Å b=19.5639(4)Å c=22.0741(5)Å
α=84.2178(13)° β=88.4073(14)° γ=83.6001(13)°
(5H-dibenz(b,f)azepine-5-carboxamide)N,N-dimethyl acetamide solvate
C19H21N3O2
CrystEngComm (2008) 10, 1 23
a=7.5046(7)Å b=19.506(2)Å c=11.7808(13)Å
α=90.00° β=96.597(8)° γ=90.00°
(5H-dibenz(b,f)azepine-5-carboxamide)nitromethane solvate
C16H15N3O3
CrystEngComm (2008) 10, 1 23
a=10.9242(11)Å b=5.1617(5)Å c=26.309(3)Å
α=90.00° β=100.104(2)° γ=90.00°
(5H-dibenz(b,f)azepine-5-carboxamide) N-methylpyrrolidine solvate
C20H21N3O2
CrystEngComm (2008) 10, 1 23
a=7.5448(4)Å b=19.5119(10)Å c=11.8783(6)Å
α=90.00° β=98.013(3)° γ=90.00°
Cytenamide form II
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=5.8100(2)Å b=19.6315(5)Å c=21.7087(6)Å
α=85.918(2)° β=86.164(2)° γ=84.482(2)°
Cytenamide form I
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=33.9078(10)Å b=33.9078(10)Å c=5.6754(2)Å
α=90° β=90° γ=120°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0093(3)Å b=22.8207(8)Å c=10.4016(4)Å
α=90° β=91.416(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1345(7)Å b=23.048(3)Å c=7.4330(8)Å
α=90° β=90.449(6)° γ=90°
30:70 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.72(Br),0.28(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.2017(6)Å b=22.3376(13)Å c=10.5639(6)Å
α=90° β=90.157(3)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0604(18)Å b=22.876(4)Å c=10.4041(19)Å
α=90° β=91.741(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=9.9973(13)Å b=22.788(3)Å c=10.4078(14)Å
α=90° β=91.2430(10)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1160(12)Å b=22.916(4)Å c=7.3818(13)Å
α=90° β=91.415(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1234(14)Å b=22.966(4)Å c=7.3986(14)Å
α=90° β=91.146(2)° γ=90°
(+-)-4'-methylmethcathinone hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1264(14)Å b=22.986(5)Å c=7.4072(14)Å
α=90° β=90.974(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1314(14)Å b=23.013(5)Å c=7.4180(15)Å
α=90° β=90.803(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1365(14)Å b=23.041(5)Å c=7.4304(15)Å
α=90° β=90.628(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=5.7804(4)Å b=19.7971(14)Å c=10.5967(6)Å
α=90° β=100.841(3)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=10.8355(19)Å b=10.2030(17)Å c=11.5425(19)Å
α=90° β=111.839(8)° γ=90°
60:40 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.4(Br),0.6(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.1409(11)Å b=22.488(3)Å c=10.4979(11)Å
α=90° β=90.359(8)° γ=90°
70:30 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16Br0.30Cl0.70N1O1
CrystEngComm (2014) 16, 26 5827
a=10.1012(5)Å b=22.5506(12)Å c=10.4737(5)Å
α=90° β=90.441(3)° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
10,11-Dihydro-5H-dibenzo(b,f)azepine-5-carboxamide
C15H14N2O
CrystEngComm (2010) 12, 1 64
a=13.207(6)Å b=5.347(2)Å c=18.891(7)Å
α=90.00° β=116.37(2)° γ=90.00°
N-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]- 3-[2-(2-naphthalen-1-ylethoxy)ethylsulfonyl]propylaminium benzoate
C26H31N2O5S2,C7H5O2
Acta Crystallographica Section E (2004) 60, 10 o1751-o1753
a=7.63122(17)Å b=13.6673(3)Å c=15.8058(5)Å
α=84.385(2)° β=87.4653(19)° γ=75.7135(13)°
3,4-dichloronitrobenzene--aniline (2/1)
2C6H3Cl2NO2,C6H7N
Acta Crystallographica Section E (2005) 61, 7 o2318-o2319
a=6.9774(2)Å b=10.1668(3)Å c=27.6762(7)Å
α=90.00° β=96.495(2)° γ=90.00°
Carbamazepine N,N-dimethylformamide solvate
C15H12N2O,C3H7N1O
Acta Crystallographica Section E (2005) 61, 5 o1509-o1511
a=7.7118(4)Å b=9.1503(4)Å c=11.6969(6)Å
α=100.192(3)° β=95.379(2)° γ=101.908(3)°
Hydrochlorothiazide N,N-dimethylformamide solvate
C7H8ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 5 o1730-o1732
a=7.3028(2)Å b=9.1492(2)Å c=23.6989(6)Å
α=86.1940(10)° β=89.8410(10)° γ=72.8550(10)°
3-Azabicyclo[3.3.1]nonane-2,4-dione
C8H11N1O2
Acta Crystallographica Section E (2006) 62, 7 o3046-o3048
a=7.67102(18)Å b=10.5483(2)Å c=18.8867(4)Å
α=90° β=95.5800(12)° γ=90°
Hydrochlorothiazide N,N-dimethylacetamide solvate (1/2)
C7H8ClN3O4S2,2C4H9NO
Acta Crystallographica Section E (2006) 62, 7 o2926-o2928
a=17.0841(6)Å b=7.3905(3)Å c=17.7937(7)Å
α=90.00° β=106.875(2)° γ=90.00°
Hydrochlorothiazide form II
C7H8ClN3O4S2
Acta Crystallographica Section E (2005) 61, 9 o2798-o2800
a=9.4884(5)Å b=8.3334(4)Å c=15.1309(7)Å
α=90° β=113.2087(19)° γ=90°
Chlorothiazide dimethylformamide solvate
C7H6ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 6 o2216-o2218
a=7.9822(4)Å b=8.8830(5)Å c=11.1075(6)Å
α=86.689(3)° β=75.078(3)° γ=73.196(3)°
Hydrochlrothiazide DMSO solvate
C7H8ClN3O4S2,C2H6OS
Acta Crystallographica Section E (2006) 62, 6 o2288-o2290
a=7.5068(4)Å b=9.8272(5)Å c=10.7311(6)Å
α=85.639(3)° β=73.896(3)° γ=80.246(3)°
Carbamazepine furfural hemisolvate
C15H12N2O,0.5C5H4O2
Acta Crystallographica Section E (2005) 61, 6 o1777-o1779
a=5.1815(4)Å b=26.0450(19)Å c=20.5735(15)Å
α=90.00° β=91.302(2)° γ=90.00°
Hydrochlorothiazide--methyl acetate (1/1)
C7H8ClN3O4S2,C3H6O2
Acta Crystallographica Section E (2005) 61, 9 o2974-o2977
a=9.39703(16)Å b=7.28424(16)Å c=21.9483(3)Å
α=90° β=95.8020(11)° γ=90°
(C6H3Cl2NO2)4.(C4H8N2)'
C6H3Cl2N1O2,0.25C4H8N2
Acta Crystallographica Section E (2005) 61, 11 o3666-o3667
a=7.3850(3)Å b=9.7359(3)Å c=13.7218(5)Å
α=69.347(2)° β=87.209(2)° γ=67.945(2)°
Cyclohexane-1,3-dicarboximide, acetic acid (1/1)
C8H11NO2,C2H4O2
Acta Crystallographica Section E (2006) 62, 2 o545-o547
a=6.6224(7)Å b=7.3580(8)Å c=10.7995(12)Å
α=103.598(2)° β=93.378(2)° γ=97.272(2)°
Hydrochlorothiazide aniline solvate
C7H8ClN3O4S2,C6H7N
Acta Crystallographica Section E (2005) 61, 8 o2520-o2522
a=9.7757(3)Å b=10.5004(3)Å c=15.6093(4)Å
α=90.00° β=91.692(2)° γ=90.00°
Hydrochlorothiazide--1,4-dioxane (1/1)
C7H8ClN3O4S2,C4H8O2
Acta Crystallographica Section E (2005) 61, 8 o2573-o2575
a=6.6684(2)Å b=9.8585(3)Å c=12.9149(4)Å
α=87.046(2)° β=78.017(2)° γ=70.872(2)°
Hydrochlorothiazide N-methyl-2-pyrrolidone disolvate
C7H8ClN3O4S2,2C5H9NO
Acta Crystallographica Section E (2006) 62, 11 o5169-o5171
a=17.0756(6)Å b=7.4819(3)Å c=17.9978(6)Å
α=90.00° β=105.211(2)° γ=90.00°
Trichlormethiazide
C8H8Cl3N3O4S2
Acta Crystallographica Section E (2007) 63, 9 o3685-o3685
a=8.7881(2)Å b=9.7924(2)Å c=15.8527(3)Å
α=90.00° β=90.00° γ=90.00°
Carbamazepine trifluoroacetic acid solvate
C15H12N2O,C2HF3O2
Acta Crystallographica Section E (2007) 63, 11 o4269-o4269
a=15.0142(4)Å b=5.28710(10)Å c=20.2489(6)Å
α=90.00° β=101.735(3)° γ=90.00°
Chlorothiazide--pyridine (1/3)
C7H6ClN3O4S2,3(C5H5N)
Acta Crystallographica Section E (2008) 64, 6 o1105-o1106
a=9.0697(15)Å b=11.863(2)Å c=11.875(2)Å
α=100.691(7)° β=98.667(8)° γ=98.134(7)°
Cytenamide acetic acid solvate
C16H13NO,C2H4O2
Acta Crystallographica Section E (2008) 64, 6 o1175-o1176
a=5.8726(17)Å b=14.418(3)Å c=18.182(4)Å
α=90° β=95.13(2)° γ=90°
Dihydrocarbamazepine formamide
C15H14N2O,CH3NO
Acta Crystallographica Section E (2007) 63, 9 o3888-o3889
a=8.4690(4)Å b=9.0215(4)Å c=10.3137(4)Å
α=74.363(3)° β=83.630(3)° γ=70.847(3)°
10,11-Dihydrocarbamazepine--dimethyl sulfoxide (1/1)
C15H14N2O1,C2H6OS
Acta Crystallographica Section E (2007) 63, 9 o3918-o3919
a=10.2696(3)Å b=6.8543(2)Å c=23.3599(6)Å
α=90.00° β=98.932(2)° γ=90.00°
Dihydrocarbamazepine Form III
C15H14N2O1
Acta Crystallographica Section E (2007) 63, 2 o675-o677
a=5.4233(12)Å b=9.200(5)Å c=24.189(6)Å
α=87.59(3)° β=84.23(2)° γ=88.93(3)°
3-azabicyclo[3.3.1]nonane-2,4-dione 1-methylnaphthalene hemisolvate
C8H11NO2,0.5C11H10
Acta Crystallographica Section E (2006) 62, 9 o3752-o3754
a=15.02360(18)Å b=7.32295(12)Å c=22.5164(3)Å
α=90° β=106.0201(6)° γ=90°
10,11-Dihydrocarbamazepine--formic acid (1/1)
C15H14N2O,CH2O2
Acta Crystallographica Section E (2007) 63, 3 o1469-o1470
a=5.2298(4)Å b=9.3849(12)Å c=14.4858(18)Å
α=83.853(5)° β=88.230(7)° γ=88.221(7)°
Chlorothiazide formic acid solvate (1/2)
C7H6ClN3O4S2,2(CH2O2)
Acta Crystallographica Section E (2007) 63, 10 o4021-o4021
a=8.2985(5)Å b=21.5271(14)Å c=8.3676(5)Å
α=90.00° β=105.580(3)° γ=90.00°
Hydroflumethiazide dimethylsulfoxide disolvate
C8H8F3N3O4S2,2C2H6OS
Acta Crystallographica Section E (2007) 63, 10 o3956-o3956
a=5.55700(10)Å b=20.8433(4)Å c=17.4142(3)Å
α=90.00° β=93.540(2)° γ=90.00°
Cytenamide--butyric acid (1/1)
C16H13NO,C4H8O2
Acta Crystallographica Section E (2008) 64, 7 o1295-o1296
a=5.9351(2)Å b=16.3595(5)Å c=17.6738(4)Å
α=90° β=98.046(2)° γ=90°
Cytenamide trifluoroacetic acid solvate
C16H13NO,C2HF3O2
Acta Crystallographica Section E (2008) 64, 7 o1215-o1216
a=12.1673(11)Å b=6.3235(6)Å c=21.4525(15)Å
α=90° β=101.932(8)° γ=90°
Cytenamide--1,4-dioxane (2/1)
2C16H13NO,C4H8O2
Acta Crystallographica Section E (2008) 64, 7 o1345-o1346
a=24.0888(7)Å b=5.6066(2)Å c=21.1050(6)Å
α=90° β=90.313(3)° γ=90°
10,11-Dihydrocarbamazepine--acetic acid (1/1)
C15H14N2O,C2H4O2
Acta Crystallographica Section E (2006) 62, 12 o5361-o5362
a=5.3104(4)Å b=15.4246(17)Å c=18.732(2)Å
α=90.00° β=95.106(7)° γ=90.00°
Cyheptamide
C16H15NO
Acta Crystallographica Section E (2007) 63, 1 o205-o206
a=5.6035(7)Å b=9.1716(11)Å c=23.579(3)Å
α=90.00° β=96.752(12)° γ=90.00°
Chlorothiazide DMSO solvate
C7H6ClN3O4S2,C2H6OS
Acta Crystallographica Section E (2007) 63, 5 o2423-o2423
a=9.0965(3)Å b=11.2081(4)Å c=15.8916(5)Å
α=109.009(2)° β=103.384(2)° γ=96.246(2)°
Chlorothiazide N,N-dimethylacetamide solvate
C7H6ClN3O4S2,2C4H9NO
Acta Crystallographica Section E (2007) 63, 5 o2422-o2422
a=8.2037(3)Å b=24.5226(6)Å c=10.6443(3)Å
α=90.00° β=105.231(2)° γ=90.00°
Cytenamide--formic acid (1/1)
C16H13NO,CH2O2
Acta Crystallographica Section E (2008) 64, 8 o1379-o1380
a=11.5351(13)Å b=13.9095(15)Å c=17.6904(19)Å
α=90.00° β=95.846(5)° γ=90.00°
Bendroflumethiazide acetone solvate
C15H14F3N3O4S2,C3H6O
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.192(2)Å b=9.525(2)Å c=14.101(2)Å
α=99.538(17)° β=100.171(17)° γ=100.42(2)°
Bendroflumethiazide N,N-dimethylformamide solvate
C15H14F3N3O4S2,C3H7NO
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.2527(3)Å b=17.8431(7)Å c=14.9012(5)Å
α=90° β=103.752(4)° γ=90°
2-[1-(Hydroxyimino)ethyl]-2,5,5-trimethylperhydropyrimidine-butane-2,3-dione monoxime (1/1)
C9H19N3O,C4H7NO2
Acta Crystallographica Section C (2001) 57, 10 1222-1224
a=6.4630(3)Å b=8.3080(5)Å c=16.3530(9)Å
α=77.095(3)° β=86.747(3)° γ=67.554(3)°
1-nitro-2,4-Dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=20.682(3)Å b=3.7484(5)Å c=20.961(3)Å
α=90.00° β=118.235(2)° γ=90.00°
1-nitro-2,5-dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=7.1403(8)Å b=7.2638(8)Å c=8.2418(9)Å
α=72.781(2)° β=70.300(2)° γ=66.349(2)°
1-Chloro-3,4-dinitrobenzene beta polymorph
C6H3ClN2O4
Crystal Growth & Design (2008) 8, 1 24
a=7.554(3)Å b=7.821(3)Å c=13.453(5)Å
α=90.00° β=96.307(7)° γ=90.00°
1-nitro-3,4-dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=27.9342(19)Å b=27.9342(19)Å c=3.7655(5)Å
α=90.00° β=90.00° γ=90.00°
1-Chloro-3,4-dinitrobenzene gamma polymorph
C6H3ClN2O4
Crystal Growth & Design (2008) 8, 1 24
a=5.5245(11)Å b=11.778(2)Å c=11.939(2)Å
α=90.00° β=90.00° γ=90.00°
C14H18MgO8
C14H18MgO8
Crystal Growth & Design (2011) 11, 4 1318
a=8.8802(16)Å b=10.4210(18)Å c=35.019(6)Å
α=90.00° β=97.228(3)° γ=90.00°
C14H12O5Sr
C14H12O5Sr
Crystal Growth & Design (2011) 11, 4 1318
a=11.8003(4)Å b=7.1674(2)Å c=15.7364(5)Å
α=90.00° β=99.998(2)° γ=90.00°
C14H12F2MgO6
C14H12F2MgO6
Crystal Growth & Design (2011) 11, 4 1318
a=7.2810(5)Å b=6.6002(4)Å c=14.6587(9)Å
α=90.00° β=99.973(3)° γ=90.00°
C14H14BaO6
C14H14BaO6
Crystal Growth & Design (2011) 11, 4 1318
a=7.5980(3)Å b=12.9258(5)Å c=30.7127(14)Å
α=90.00° β=94.956(2)° γ=90.00°
C14H17.48F2O8.74Sr
C14H17.48F2O8.74Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.7231(3)Å b=7.4076(3)Å c=16.6220(10)Å
α=82.951(4)° β=89.380(4)° γ=84.302(4)°
C14H8BaF2O4
C14H8BaF2O4
Crystal Growth & Design (2011) 11, 4 1318
a=10.3942(5)Å b=7.7929(5)Å c=16.1632(10)Å
α=90.00° β=103.679(4)° γ=90.00°
C14H16Cl2MgO8
C14H16Cl2MgO8
Crystal Growth & Design (2011) 11, 4 1318
a=39.8060(18)Å b=10.3870(5)Å c=8.8480(4)Å
α=90.00° β=91.039(2)° γ=90.00°
C14H14CaCl2O7
C14H14CaCl2O7
Crystal Growth & Design (2011) 11, 4 1318
a=6.5797(9)Å b=34.867(5)Å c=7.1797(11)Å
α=90.00° β=93.184(5)° γ=90.00°
C14H16Cl2O8Sr
C14H16Cl2O8Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.7800(2)Å b=7.5071(2)Å c=17.5087(5)Å
α=81.9304(14)° β=89.7850(15)° γ=83.9229(16)°
C14H16BaCl2O8
C14H16BaCl2O8
Crystal Growth & Design (2011) 11, 4 1318
a=7.0487(5)Å b=7.6124(5)Å c=17.3085(14)Å
α=80.425(6)° β=89.215(6)° γ=82.281(6)°
C14H16CaN2O6
C14H16CaN2O6
Crystal Growth & Design (2011) 11, 4 1318
a=6.607(2)Å b=13.075(3)Å c=18.444(4)Å
α=90.00° β=90.00° γ=90.00°
C14H24MgN2O16
C14H24MgN2O16
Crystal Growth & Design (2011) 11, 4 1318
a=13.8735(6)Å b=14.1004(5)Å c=14.0354(6)Å
α=86.534(2)° β=62.119(2)° γ=62.583(2)°
C14H26CaN2O17
C14H26CaN2O17
Crystal Growth & Design (2011) 11, 4 1318
a=15.093(2)Å b=9.9490(5)Å c=15.713(2)Å
α=90.00° β=94.767(2)° γ=90.00°
C14H26N2O17Sr
C14H26N2O17Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.6527(6)Å b=11.1343(10)Å c=31.494(3)Å
α=90.00° β=94.882(4)° γ=90.00°
C14H18BaN2O13
C14H18BaN2O13
Crystal Growth & Design (2011) 11, 4 1318
a=6.5280(2)Å b=10.6570(3)Å c=28.3021(5)Å
α=90.00° β=91.1560(10)° γ=90.00°
C14H16MgN2O12
C14H16MgN2O12
Crystal Growth & Design (2011) 11, 4 1318
a=5.2497(5)Å b=7.6168(8)Å c=11.7111(13)Å
α=81.763(4)° β=78.428(5)° γ=73.836(5)°
C14H16N2O12Sr
C14H16N2O12Sr
Crystal Growth & Design (2011) 11, 4 1318
a=4.0818(3)Å b=31.856(2)Å c=6.800(4)Å
α=90.00° β=94.378(3)° γ=90.00°
C14H12CaN2O10
C14H12CaN2O10
Crystal Growth & Design (2011) 11, 4 1318
a=7.7232(2)Å b=10.1673(3)Å c=11.1947(3)Å
α=81.3530(10)° β=82.231(2)° γ=89.441(2)°
C14H14BaN2O11
C14H14BaN2O11
Crystal Growth & Design (2011) 11, 4 1318
a=8.2858(2)Å b=8.3482(1)Å c=13.8501(3)Å
α=80.492(1)° β=85.986(1)° γ=71.065(1)°
C14H18BaN2O9
C14H18BaN2O9
Crystal Growth & Design (2011) 11, 4 1318
a=13.0200(4)Å b=4.3220(1)Å c=15.3326(5)Å
α=90.00° β=104.740(1)° γ=90.00°
C14H16.9BaN2O6.45
C14H16.9BaN2O6.45
Crystal Growth & Design (2011) 11, 4 1318
a=33.755(2)Å b=12.908(2)Å c=7.542(2)Å
α=90.00° β=96.02(2)° γ=90.00°
C14H13CaN2O6.5
C14H13CaN2O6.5
Crystal Growth & Design (2011) 11, 4 1318
a=14.9499(6)Å b=8.8062(4)Å c=22.3285(9)Å
α=90.00° β=104.359(3)° γ=90.00°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
C14H12BaO7
C14H12BaO7
Crystal Growth & Design (2011) 11, 4 1318
a=9.2329(2)Å b=10.0390(3)Å c=15.6860(5)Å
α=101.0560(10)° β=98.483(2)° γ=99.498(2)°
C14H13N2O6.5Sr
C14H13N2O6.5Sr
Crystal Growth & Design (2011) 11, 4 1318
a=15.146(1)Å b=9.0220(6)Å c=22.492(1)Å
α=90.00° β=105.794(1)° γ=90.00°
Bis[4-(Trifluoromethyl)benzylammonium] Lead(II) Tetraiodide; [4-(Trifluoromethyl)benzylammonium]2PbI4
I4Pb,2(C8H9F3N)
The journal of physical chemistry letters (2020) 11, 23 10144-10149
a=18.1441(13)Å b=8.4180(5)Å c=8.6907(6)Å
α=90° β=98.909(2)° γ=90°